SynthesisThe Cochrane database of systematic reviews2010
Quinine for muscle cramps.
Synthesis in The Cochrane database of systematic reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 6 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Criteria in diagnosing nocturnal leg cramps: a systematic review.BMC family practice · 2017Pooled it
- Quinine for muscle cramps.The Cochrane database of systematic reviews · 2015Pooled it
- Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease.The Cochrane database of systematic reviews · 2013Pooled it
- Magnesium for skeletal muscle cramps.The Cochrane database of systematic reviews · 2012Pooled it
- Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease.The Cochrane database of systematic reviews · 2012Pooled it
- Non-drug therapies for lower limb muscle cramps.The Cochrane database of systematic reviews · 2012Pooled it
- Quinine Use and the Risk of Exacerbations of Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Registry Study.International journal of chronic obstructive pulmonary disease · 2025Article
- An Evidence-Based Review of the Pathophysiology, Treatment, and Prevention of Exercise-Associated Muscle Cramps.Journal of athletic training · 2022Review
- Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial.Muscle & nerve · 2018Article
- Treatment of nocturnal leg cramps by blockade of the medial branch of the deep peroneal nerve after lumbar spine surgery.Brain and behavior · 2015Article
- Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.Current hypertension reports · 2015Review
- Quinine: not a safe drug for treating nocturnal leg cramps.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Article
- Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.NeuroRehabilitation · 2015Review
- Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC · 2014Article
- Muscle cramps in liver disease.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2013Review
- Neurologist practice patterns in treatment of muscle cramps in Canada.Journal of foot and ankle research · 2013Article
- Plasmodium drug targets outside the genetic control of the parasite.Current pharmaceutical design · 2013Review
- Prevalence and morbidity associated with muscle cramps in patients with cirrhosis.The American journal of medicine · 2012Article
- Unknotting night-time muscle cramp: a survey of patient experience, help-seeking behaviour and perceived treatment effectiveness.Journal of foot and ankle research · 2012Article
- Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Advances in hematology · 2012Article
Corrections and comments
- Commented on by
- Updated by
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMuscle cramps can occur anywhere and for many reasons. Quinine has been used to treat cramps of all causes. However, controversy continues about its efficacy and safety.
objectivesTo assess the efficacy and safety of quinine in treating muscle cramps. SEARCH STRATEGY: We searched The Cochrane Neuromuscular Disease Group Register, The Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3, 2010), MEDLINE, EMBASE and reference lists of articles up to July 2010. SELECTION CRITERIA: Randomised controlled trials of people of all ages with muscle cramps in any location and of any cause, treated with quinine or its derivatives. DATA COLLECTION AND ANALYSIS: Three authors independently selected trials for inclusion, assessed risk of bias and extracted data. We contacted study authors for additional information. MAIN
resultsWe identified 23 trials with a total of 1586 participants. Fifty-eight per cent of these participants were from five unpublished studies. Quinine was compared to placebo (20 trials, n =1140), vitamin E (four trials, n = 543), a quinine-vitamin E combination (three trials, n = 510), a quinine-theophylline combination (one trial, n = 77), and xylocaine injections into the gastrocnemius muscle (one trial, n = 24). The most commonly used quinine dosage was 300 mg/day (range 200 to 500 mg).Compared to placebo, quinine significantly reduced cramp number over two weeks by 28%, cramp intensity by 10%, and cramp days by 20%. Cramp duration was not significantly affected.A significantly greater number of people suffered minor adverse events on quinine than placebo (risk difference +3%, 95% confidence intervals 0% to 6%), mainly gastrointestinal symptoms. Overdoses of quinine have been reported elsewhere to cause potentially fatal adverse effects, but in the included trials there was no significant difference in major adverse events compared with placebo (risk difference 0%, 95% confidence intervals -1% to 2%). One participant suffered from thrombocytopenia (0.12% risk) on quinine.A quinine-vitamin E combination, vitamin E alone, and xylocaine injections into gastrocnemius were not significantly different to quinine across all outcomes, including adverse effects. Based on a single trial comparison, quinine alone was significantly less effective than a quinine-theophylline combination but with no significant differences in adverse events. AUTHORS'
conclusionsThere is moderate quality evidence that quinine significantly reduces cramp frequency, intensity and cramp days in dosages between 200 and 500 mg/day. There is moderate quality evidence that with use up to 60 days, the incidence of serious adverse events is not significantly greater than for placebo in the identified trials. Further research is required on the optimal dose and duration of use, and also on alternative treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.